REGENXBIO Inc. (RGNX) Wednesday reported additional positive results from the Phase I/II AFFINITY DUCHENNE trial of RGX-202 in patients with Duchenne muscular dystrophy.
The Phase I/II AFFINITY DUCHENNE trial is designed to evaluate the safety, tolerability and clinical efficacy of a one-time intravenous (IV) dose of RGX-202 in patients with Duchenne.
As per new data, a patient aged 6.6 years old, who received RGX-202 at dose level 1, had microdystrophin expression level at 83.4% of control at three months. A reduction from baseline in serum creatinine kinase (CK) levels of 93% was observed at ten weeks.
The company said it is on track to initiate pivotal trial in second half of 2024.
REGENXBIO shares are up more than 14% in pre-market. The stock had closed at $13.05, up 5.93% on Tuesday. It has traded in the range of $11.83 - $25.32 in the last 1 year.
For comments and feedback contact: editorial@rttnews.com
Business News
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.